The clinical relevance of circulating, cell-free and exosomal micrornas as biomarkers for gynecological tumors
|
|
- Marybeth Casey
- 6 years ago
- Views:
Transcription
1 Department of Tumor Biology The clinical relevance of circulating, cell-free and exosomal micrornas as biomarkers for gynecological tumors cfdna Copenhagen April 6-7, 2017 Heidi Schwarzenbach, PhD
2 Tumor cells release their nucleic acids into the blood circulation Schwarzenbach et al., Nat Rev Cancer 2011
3 Postoperative tumor rest contributes to the increased serum levels of circulating DNA in ovarian cancer patients Wimberger Schwarzenbach, Int J Cancer, 2011
4 Cell-free DNA circulates as nucleosomes in the blood of breast cancer patients Roth Schwarzenbach, BMC Cancer 2011
5 The elevated serum levels of circulating nucleosomes in breast cancer patients are caused by caspases 3 and 7 which are involved in the apoptosis of tumor cells Apoptosis DNA Fragmentation Roth Schwarzenbach, BMC Cancer 2011 DNases
6 Increased serum levels of circulating protease activities in breast cancer patients at advanced tumor stages or with metastasis Roth Schwarzenbach, BMC Cancer 2011
7 Association of increased serum levels of circulating protease activities with disseminated tumor cells in bone marrow of ovarian cancer patients Wimberger, Schwarzenbach, Int J Cancer, 2011 Degradation of the extracellular matrix by proteases supports the dissemination of tumor cells.
8 MicroRNAs Non-coding RNA molecules of ~22 nucleotides Binding to hundreds of different mrnas resulting in the regulation of various signal pathways Apoptosis, cell differentiation, neural development, tumorigenesis, metastasis Frequent location in fragile chromosomal regions exhibiting amplifications, deletions or translocations Translational inhibition mrna-degradation protein expression Degraded mrnas
9 microrna expression profile in the plasma of breast cancer patients Breast cancer patients vs. healthy women micrornas Median fold change P-Values mir-27a mir mir-130a mir Stückrath Schwarzenbach, Oncotarget 2015
10 Increased plasma levels of mir-130a in HER2-positive and lymph node-negative breast cancer patients, and their effect on cell proliferation p=0.006 p=0.001 p=0.027 p=0.001 Stückrath Schwarzenbach, Oncotarget 2015
11 Decreased serum levels of mir-155 in metastatic breast cancer patients and their epigenetic regulation p= mir-155 expression Treatment of breast cancer cells with the demethylation agent 5-aza-desoxycytidine and the histone deacetylase inhibitor TSA increased the expression of mir-155, but TSA could not further stimulate the 5-aza-desoxycytidine mediated upregulation of mir-155. Eichelser Schwarzenbach, Clin Chem 2013
12 Serum PTEN-targeting mir-214 discriminates malignant from benign breast tumors (n = 53) (n = 32) (n = 102) MiR-214 targets the tumor suppressor PTEN which controls the phosphoinositide 3-kinase signaling pathway The upregulated, preoperative levels of mir-214 significantly decreases in the postoperative serum. Schwarzenbach et al. Breast Cancer Res Treat. 2012
13 Increased serum levels of mir-21, mir-210 and mir-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy combined with either trastuzumab or lapatinib before after Neoadjuvant Therapy mir-21 mir-21 Relative microrna levels mir-210 mir-373 mir-210 mir-373 Healthy Breast Cancer Healthy Beast Cancer Müller Schwarzenbach, Breast Cancer Res Treat 2014
14 Changes in the serum levels of mir-21, mir-210 and mir-373 in HER2- positive breast cancer patients undergoing neoadjuvant therapy combined with either trastuzumab or lapatinib Relative microrna levels mir-21 mir-210 mir-373 before after Neoadjuvant Therapy before after Neoadjuvant Therapy before after Neoadjuvant Therapy Müller Schwarzenbach, Breast Cancer Res Treat 2014
15 Higher serum levels of cell-free mir-21 are associated with a shorter overall survival of HER2-positive breast cancer patients before and after neoadjuvant therapy Survival Probability Survival Probability Time (months) Time (months) Müller Schwarzenbach, Breast Cancer Res Treat 2014
16 Elevated serum concentrations of cell-free mir-429 are associated with FIGO stages, tumor rest and tumor marker CA125 values in ovarian cancer patients p= p=0.001 p=0.005 p=0.03 r= FIGO I: Tumor limited to the ovaries FIGO II: Tumor involves ovaries with pelvic extension FIGO III: Tumor involves ovaries with peritoneal metastasis outside the pelvis FIGO: IV: Distant metastasis Meng Schwarzenbach, Brit. J. Cancer 2015
17 Higher serum levels of circulating, cell-free mir-429 predict poor overall survival in ovarian cancer patients p=0.011 Survival Probability below median above median Time (months) Meng Schwarzenbach, Brit. J. Cancer 2015
18 Mechanisms of release of micrornas into the blood circulation Cell-free micrornas incorporated in apoptotic bodies Schwarzenbach et al., Nat. Rev. Clin. Oncol. 2014
19 Elevated serum levels of exosomes in ovarian cancer patients Ovarian Cancer Western Blot Mucin1 CD63 CD9 Schwarzenbach, Expert Rev Mol Diagn. 2015
20 Exosomes visualized by FISH Cell nucleus was stained by DAPI Exosomes were stained by Exo-Red
21 Predominant circulation of exosomal micrornas in the blood of breast cancer patients Relative microrna concentrations p=0.021 mir-101 mir-372 mir-373 Eichelser Schwarzenbach, Oncotarget, 2014
22 Increased levels of exosomal mir-373 in the serum of estrogen receptor-negative breast cancer patients Relative mir-373 concentrations p=0.006 p=0.001 Cell-free p=0.001 p=0.021 Exosomal 70kDa 70kDa Downregulation of the estrogen receptor by mir-373. plasmid mir-373 Basal empty mir-373 mimic inhibitor ER HSC70 Eichelser Schwarzenbach, Oncotarget, 2014
23 mir-373 inhibits the apoptosis of MCF-7 cells mediated by camptothecin Control mir-373 +Camptothecin mir-373 +Camptothecin MCF-7 cells transfected with mir-373 and treated with the topoisomerase I inhibitor camptothecin. Camptothecin, which is used in cancer chemotherapy, induces apoptosis. Eichelser Schwarzenbach, Oncotarget, 2014
24 Diagnostic relevance of exosomal mir-373, mir-200a, mir-200b and mir-200c in the serum of ovarian cancer patients Relative exosomal mirna concentrations p=0.003 p=0.004 p=0.033 p=0.004 mir-373 mir-200a mir-200b mir-200c The serum levels of exosomal mir-373 and mir-200a are upregulated in lymph node-negative (N0) and -positive (N1) patients. The serum levels of exosomal mir-200b and mir-200c differentiate between lymph node-negative (N0) and -positive (N1) patients. Meng Schwarzenbach, Oncotarget 2016
25 Relative exosomal mirna concentrations Diagnostic relevance of exosomal mir-373, mir-200a, mir- 200b and mir-200c in the serum of ovarian cancer patients **** *** * ** ** *** *** mir-373 mir-200a mir-200b mir-200c * *** *** *** * p ** p=0.002 *** The serum levels of exosomal mir- 373 and mir-200a are increased in all FIGO stages. The serum levels of exosomal mir- 200b and mir-200c differentiate between FIGO I-III and FIGO IV. FIGO I: Tumor limited to the ovaries FIGO II: Tumor involves ovaries with pelvic extension FIGO III: Tumor involves ovaries with peritoneal metastasis outside the pelvis FIGO: IV: Distant metastasis
26 The serum levels of exosomal mir-200b and mir-200c correlate with the tumor marker CA125 values in ovarian cancer patients mir-200a r=0.203 p=0.076 mir-200b r=0.438 mir-200c r= a 200b 200c Meng Schwarzenbach, Oncotarget 2016
27 Higher serum levels of exosomal mir-200b and mir-200c predict poor overall survival in ovarian cancer patients mir-200a mir-200b mir-200c Survival Probability p=0.22 below median above median Survival Probability p=0.007 below median above median Survival Probability p=0.017 below median above median Time (months) Time (months) Time (months) Meng Schwarzenbach, Oncotarget 2016
28 Conclusion Deregulation of cell-free and exosomal micrornas in the blood of breast and ovarian cancer patients. Diagnostic and prognostic relevance of cell-free and exosomal micrornas in the blood of breast and ovarian cancer patients. Changes in the serum levels of cell-free micrornas in HER2- positive breast cancer patients undergoing neoadjuvant therapy Predominant circulation of micrornas in exosomes in the blood of breast cancer patients. Correlations of serum concentrations of micrornas with tumor marker CA125, tumor stage, tumor rest and receptor status. Associations of micrornas with apoptosis and proliferation in cancer cell lines.
29 Conclusion A promising new class of potential liquid biomarkers. Extraction of micrornas from exosomes derived from blood plasma and serum in real-time. Screening of these micrornas provides information about the deregulated signaling pathways that can be blocked by a targeted therapy. Quantification of micrornas can facilitate decisions in the treatment of cancer patients. Schwarzenbach, Exp Rev Diagn 2014
30 Acknowledgments Dr. Carina Roth Dr. Xiaodan Meng Dr. Isabel Stückrath Dr. Corinna Eichelser Bettina Steinbach Prof. Klaus Pantel (University Medical Center Hamburg-Eppendorf, Germany) Prof. Dr. Volkmar Müller (University Medical Center Hamburg-Eppendorf, Germany) Prof. Dr. Wolfgang Janni (Heinrich Heine University, Düsseldorf, Germany) Erich und Gertrud Roggenbuck-Stiftung zur Förderung der Krebsforschung Dr. Brigitte Rack (Ludwig Maximilians University of Munich, Germany)
31 Thanks for your attention A long way to cure cancer Hamburg, Germany
mirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationProducts for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma
MACHEREY-NAGEL Products for cfdna and mirna isolation Bioanalysis Subhead Circulating Cover nucleic acids from plasma n Flexible solutions for small and large blood plasma volumes n Highly efficient recovery
More informationCancer Problems in Indonesia
mirna and Cancer : mirna as a Key Regulator in Cancer Sofia Mubarika 2 nd Symposium Biomolecular Update in Cancer PERABOI Padang 18 Mei 2013 Cancer Problems in Indonesia 1. Chemoresistency / recurrency
More informationOverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA
OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.
More informationExosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study
GBCC 2017: ABS-0017 Exosomal Del 1 as a potent diagnostic marker for breast cancer : A prospective cohort study Soo Jung Lee 1, Jeeyeon Lee 2, Jin Hyang Jung 2, Ho Yong Park 2, Chan Hyeong Lee 3, Pyong
More informationOS related to CTC response (response: 30% decline) 4 weeks 8 weeks 12 weeks
OS related to CTC response (response: 30% decline) 4 weeks 8 weeks 12 weeks 20 CTC characterization (DNA, RNA, proteins) - Therapeutic targets - Resistance mechanisms Detection of therapeutic targets on
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationIntegrated platform for liquid biopsy-based personalized cancer medicine
Integrated platform for liquid biopsy-based personalized cancer medicine Dr. Bernhard Polzer Fraunhofer ITEM-Regensburg Personalized Tumor Therapy Personalized cancer therapy Primary tumor single tumor
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationLiquid Biopsy: Implications for Cancer Staging & Therapy
Prof. Klaus Pantel, MD, PhD Institut für Tumorbiologie Liquid Biopsy: Implications for Cancer Staging & Therapy Tumor cell dissemination and cancer dormancy Primary tumor Local relapse Cancer cells disseminate
More informationCirculating Tumor Cells in non- Metastatic Triple Negative Breast Cancer
Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Carolyn Hall, Ph.D. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Triple Negative Breast Cancer
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationSoft Agar Assay. For each cell pool, 100,000 cells were resuspended in 0.35% (w/v)
SUPPLEMENTARY MATERIAL AND METHODS Soft Agar Assay. For each cell pool, 100,000 cells were resuspended in 0.35% (w/v) top agar (LONZA, SeaKem LE Agarose cat.5004) and plated onto 0.5% (w/v) basal agar.
More informationINTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for
INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for more deaths than both cervical and endometrial tumours.
More informationMicroRNA-29a Reveals Oncogenic Role on Myeloid Malignancies by Regulating DNMT3A
MicroRNA-29a Reveals Oncogenic Role on Myeloid Malignancies by Regulating DNMT3A Heba Alkhatabi, PhD Assistant Professor Department of Medical Laboratory Collage of Applied Medical science King Abdul Aziz
More informationDecreased expression of mir-490-3p in osteosarcoma and its clinical significance
European Review for Medical and Pharmacological Sciences Decreased expression of mir-490-3p in osteosarcoma and its clinical significance B. TANG, C. LIU, Q.-M. ZHANG, M. NI Department of Orthopedics,
More informationGENE EXPRESSION AND microrna PROFILING IN LYMPHOMAS. AN INTEGRATIVE GENOMICS ANALYSIS
GENE EXPRESSION AND microrna PROFILING IN LYMPHOMAS. AN INTEGRATIVE GENOMICS ANALYSIS Dra. Margarita Sánchez-Beato Lymphoma Group Molecular Pathology Programme CNIO Agilent Microarray and Sequencing Roadshow,
More informationSupplementary Figure S1. Venn diagram analysis of mrna microarray data and mirna target analysis. (a) Western blot analysis of T lymphoblasts (CLS)
Supplementary Figure S1. Venn diagram analysis of mrna microarray data and mirna target analysis. (a) Western blot analysis of T lymphoblasts (CLS) and their exosomes (EXO) in resting (REST) and activated
More informationSection D: The Molecular Biology of Cancer
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Section D: The Molecular Biology of Cancer 1. Cancer results from genetic changes that affect the cell cycle 2. Oncogene proteins and faulty
More informationOriginal Article MicroRNA-101 is a novel biomarker for diagnosis and prognosis in breast cancer
Int J Clin Exp Pathol 2017;10(3):3279-3285 www.ijcep.com /ISSN:1936-2625/IJCEP0022926 Original Article MicroRNA-101 is a novel biomarker for diagnosis and prognosis in breast cancer Na Wei, Qing Ni, Min
More informationBerberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through mir-93/ PTEN/Akt Signaling Pathway
Chen Accepted: et al.: February Berberine 24, Sensitizes 2015 Ovarian Cancer Cells to Cisplatin www.karger.com/cpb 956 1421-9778/15/0363-0956$39.50/0 Original Paper This is an Open Access article licensed
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationMicroRNAs: a new source of biomarkers in radiation response. Simone Moertl, Helmholtz Centre Munich
MicroRNAs: a new source of biomarkers in radiation response Simone Moertl, Helmholtz Centre Munich The RNA World mrna rrna coding snorna trna scarna RNA snrna noncoding lincrna rasirna RNAi anti-sense
More informationCirculating tumour DNA in breast cancer. Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho
Circulating tumour DNA in breast cancer Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho Conflicts of Interest I have no financial relationships to disclose I will
More informationNovel Biomarkers (Kallikreins) for Prognosis and Therapy Response in Ovarian cancer
Novel Biomarkers (Kallikreins) for Prognosis and Therapy Response in Ovarian cancer Eleftherios P. Diamandis, M.D., Ph.D., FRCP(C) EORTC-NCI-ASCO Meeting,November 16, 2007 Yousef GM, Diamandis EP. Endocr.
More informationIntroduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
More informationCh. 18 Regulation of Gene Expression
Ch. 18 Regulation of Gene Expression 1 Human genome has around 23,688 genes (Scientific American 2/2006) Essential Questions: How is transcription regulated? How are genes expressed? 2 Bacteria regulate
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationGenome of Hepatitis B Virus. VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department
Genome of Hepatitis B Virus VIRAL ONCOGENE Dr. Yahwardiah Siregar, PhD Dr. Sry Suryani Widjaja, Mkes Biochemistry Department Proto Oncogen and Oncogen Oncogen Proteins that possess the ability to cause
More informationMicroRNA-92gene expression in epithelial ovarian cancer using a novel Real-Time Polymerase change reaction
www.muthjm.com Muthanna Medical Journal 2016; 3(1):23-33 MicroRNA-92gene expression in epithelial ovarian cancer using a novel Real-Time Polymerase change reaction Shoroq Mohammed AL-Temimi 1* Abstract
More informationMicroRNAs: novel regulators in skin research
MicroRNAs: novel regulators in skin research Eniko Sonkoly, Andor Pivarcsi KI, Department of Medicine, Unit of Dermatology and Venerology What are micrornas? Small, ~21-mer RNAs 1993: The first mirna discovered,
More informationMicroRNA dysregulation in cancer. Systems Plant Microbiology Hyun-Hee Lee
MicroRNA dysregulation in cancer Systems Plant Microbiology Hyun-Hee Lee Contents 1 What is MicroRNA? 2 mirna dysregulation in cancer 3 Summary What is MicroRNA? What is MicroRNA? MicroRNAs (mirnas) -
More informationLow levels of serum mir-99a is a predictor of poor prognosis in breast cancer
Low levels of serum mir-99a is a predictor of poor prognosis in breast cancer J. Li 1, Z.J. Song 2, Y.Y. Wang 1, Y. Yin 1, Y. Liu 1 and X. Nan 1 1 Tumor Research Department, Shaanxi Provincial Tumor Hospital,
More informationMicroRNA in Cancer Karen Dybkær 2013
MicroRNA in Cancer Karen Dybkær RNA Ribonucleic acid Types -Coding: messenger RNA (mrna) coding for proteins -Non-coding regulating protein formation Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationBmi-1 regulates stem cell-like properties of gastric cancer cells via modulating mirnas
Wang et al. Journal of Hematology & Oncology (2016) 9:90 DOI 10.1186/s13045-016-0323-9 RESEARCH Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating mirnas Open Access Xiaofeng
More informationMir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2017; 21: 4278-4282 Mir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer Q.-H. ZHOU 1, Y.-M. ZHAO 2, L.-L.
More informationThe Diagnostic and Prognostic Role of Serum MicroRNAs in Ovarian Cancer
The Diagnostic and Prognostic Role of Serum MicroRNAs in Ovarian Cancer Yin Min (First author) Medical College of Qingdao University, Qingdao, Shandong Province, China Chen Aiping (Corresponding author)
More informationInvited Re vie W. Molecular genetics of ovarian carcinomas. Histology and Histo pathology
Histol Histopathol (1 999) 14: 269-277 http://www.ehu.es/histol-histopathol Histology and Histo pathology Invited Re vie W Molecular genetics of ovarian carcinomas J. Diebold Pathological Institute, Ludwig-Maximilians-University
More informationSUPPLEMENTAY FIGURES AND TABLES
SUPPLEMENTAY FIGURES AND TABLES Supplementary Figure S1: Validation of mir expression by quantitative real-time PCR and time course studies on mir- 29a-3p and mir-210-3p. A. The graphs illustrate the expression
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationRegulation of Gene Expression in Eukaryotes
Ch. 19 Regulation of Gene Expression in Eukaryotes BIOL 222 Differential Gene Expression in Eukaryotes Signal Cells in a multicellular eukaryotic organism genetically identical differential gene expression
More information1.5. Research Areas Treatment Selection
1.5. Research Areas Cancer biomarker research embraces many areas of study, including tumorigenesis, metastasis, clinical trial and surrogate endpoints, cell isolation, target identification, drug resistance,
More informationTHE ROLE OF CIRCULATING TUMOUR CELLS (CTCS) IN CANCER MANAGEMENT. Klaus Pantel, MD, PhD Chairman, Institute for Tumour Biology
THE ROLE OF CIRCULATING TUMOUR CELLS (CTCS) IN CANCER MANAGEMENT Klaus Pantel, MD, PhD Chairman, Institute for Tumour Biology AIMS OF RESEARCH ON CTCS & CTDNA Screening & early detection of cancer Estimation
More informationPart-4. Cell cycle regulatory protein 5 (Cdk5) A novel target of ERK in Carb induced cell death
Part-4 Cell cycle regulatory protein 5 (Cdk5) A novel target of ERK in Carb induced cell death 95 1. Introduction The process of replicating DNA and dividing cells can be described as a series of coordinated
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationChemoresistance: Detectors to Dormancy
Chemoresistance: Detectors to Dormancy Andy Redfern University of Western Australia Harry Perkins Institute of Medical Research Fiona Stanley Hospital Ongoing Projects: What to pack? The Route to Efficacy
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationDNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA
DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias
More informationSUPPLEMENTARY INFORMATION
DOI:.38/ncb3399 a b c d FSP DAPI 5mm mm 5mm 5mm e Correspond to melanoma in-situ Figure a DCT FSP- f MITF mm mm MlanaA melanoma in-situ DCT 5mm FSP- mm mm mm mm mm g melanoma in-situ MITF MlanaA mm mm
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download: http://testbankair.com/download/test-bank-for-robbins-cotran-pathologic-basis-of-disease-9th-edition-bykumar-abbas-and-aster Test Bank for Robbins and Cotran Pathologic Basis of Disease
More informationupa: From Pilot Studies to Recommendation for Clinical Use Professor Joe Duffy St Vincent s University Hospital,
upa: From Pilot Studies to Recommendation for Clinical Use Professor Joe Duffy St Vincent s University Hospital, Dublin and University College Dublin Most Important t Questions After a Diagnosis of Breast
More informationmir-218 tissue expression level is associated with aggressive progression of gastric cancer
mir-218 tissue expression level is associated with aggressive progression of gastric cancer X.X. Wang 1, S.J. Ge 2, X.L. Wang 2, L.X. Jiang 1, M.F. Sheng 2 and J.J. Ma 2 1 Department of General Surgery,
More informationSupplementary Online Content
Supplementary Online Content Fumagalli D, Venet D, Ignatiadis M, et al. RNA Sequencing to predict response to neoadjuvant anti-her2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial.
More informationmicrorna-200b and microrna-200c promote colorectal cancer cell proliferation via
Supplementary Materials microrna-200b and microrna-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs Supplementary Table 1.
More informationPros and cons of liquid biopsy: Ready to replace tissue?
Pros and cons of liquid biopsy: Ready to replace tissue? 2-Day Molecular Biologists Symposium: Liquid biopsies Federico Rojo Enterprise Interest No disclosures. Biological limitations for molecular testing:
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationCELL BIOLOGY - CLUTCH CH CANCER.
!! www.clutchprep.com CONCEPT: OVERVIEW OF CANCER Cancer is a disease which is primarily caused from misregulated cell division, which form There are two types of tumors - Benign tumors remain confined
More informationa) List of KMTs targeted in the shrna screen. The official symbol, KMT designation,
Supplementary Information Supplementary Figures Supplementary Figure 1. a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation, gene ID and specifities are provided. Those highlighted
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationSelective filtering defect at the axon initial segment in Alzheimer s disease mouse models. Yu Wu
Selective filtering defect at the axon initial segment in Alzheimer s disease mouse models Yu Wu Alzheimer s Disease (AD) Mouse models: APP/PS1, PS1δE9, APPswe, hps1 Wirths, O. et al, Acta neuropathologica
More informationEGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationPrepared by: Dr.Mansour Al-Yazji
C L L CLL Prepared by: Abd El-Hakeem Abd El-Rahman Abu Naser Ahmed Khamis Abu Warda Ahmed Mohammed Abu Ghaben Bassel Ziad Abu Warda Nedal Mostafa El-Nahhal Dr.Mansour Al-Yazji LEUKEMIA Leukemia is a form
More informationCirculating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego
National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty
More informationSupplemental Data. TGF-β-mediated mir-181a expression promotes breast cancer metastasis by targeting Bim.
Supplemental Data TGF-β-mediated mir-181a expression promotes breast cancer metastasis by targeting Bim. Molly A. Taylor 1, Khalid Sossey-Alaoui 2, Cheryl L. Thompson 3, David Danielpour 4, and William
More informationmicro-rnas as biomarkers in children who underwent surgery for CHD
micro-rnas as biomarkers in children who underwent surgery for CHD mentors: Dr. Yael Nevo-Caspi & Prof. Gidi Paret Or Bercovich Liat Mor What will we talk about Congenital heart defects (CHD) Scientific
More informationOriginal Article Up-regulation of mir-10a and down-regulation of mir-148b serve as potential prognostic biomarkers for osteosarcoma
Int J Clin Exp Pathol 2016;9(1):186-190 www.ijcep.com /ISSN:1936-2625/IJCEP0018032 Original Article Up-regulation of mir-10a and down-regulation of mir-148b serve as potential prognostic biomarkers for
More informationEts-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs
Ets-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs Indian Patent Application No. 1623/DEL/2014 Inventors: Prof. Kulbhushan Tikoo and Jasmine Kaur Department of Pharmacology
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationmaintrac What's the future in precision diagnostics? From screening to stem cells and back!
maintrac What's the future in precision diagnostics? From screening to stem cells and back! Cancer is a frightening diagnosis: why? Malignant tumours are detectable when they have reached a size of about
More informationBreast Cancer: Who Gets It? Who Survives? The Latest Information
Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine
More informationUNIVERSITY TEKNOLOGI MARA THE ANTI PROLIFERATIVE PROPERTIES OF TINOSPORA CRISPA ON TRIPLE NEGATIVE BREAST CANCER CELL LINES
UNIVERSITY TEKNOLOGI MARA THE ANTI PROLIFERATIVE PROPERTIES OF TINOSPORA CRISPA ON TRIPLE NEGATIVE BREAST CANCER CELL LINES REYADH RADHI AL-RASHIDI Thesis submitted in fulfillment of the requirements for
More informationMammaPrint, the story of the 70-gene profile
MammaPrint, the story of the 70-gene profile René Bernards Professor of Molecular Carcinogenesis The Netherlands Cancer Institute Amsterdam Chief Scientific Officer Agendia Amsterdam The breast cancer
More informationMonitoring Metastatic Breast Cancer with Serum HER-2/neu: Individual Patient Profiles
Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the
More informationBCHM3972 Human Molecular Cell Biology (Advanced) 2013 Course University of Sydney
BCHM3972 Human Molecular Cell Biology (Advanced) 2013 Course University of Sydney Page 2: Immune Mechanisms & Molecular Biology of Host Defence (Prof Campbell) Page 45: Infection and Implications for Cell
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationLet s start first reviewing the clinical and pathological features of IBC.
Welcome to this educational event sponsored by [The University of Texas] MD Anderson Cancer Center, entitled Inflammatory Breast Cancer: Biological Features. I am Massimo Cristofanilli. I m a Professor
More informationPersonalized oncology: the potential for tissue and cell-free DNA
Open Citation: J Med Discov (2016); 1(1):jmd16005; doi:10.24262/jmd.1.1.16005 Commentary Personalized oncology: the potential for tissue and cell-free DNA biopsies to capture tumor heterogeneity Young
More informationTargeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example
Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationTitle page. Title: MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in
Title page Title: MicroRNA- Controls Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma Authors Manabu Mikamori, Daisaku Yamada, Hidetoshi Eguchi, Shinichiro Hasegawa, Tomoya
More informationYoungnam Cho. National Cancer Center Biomarker Branch
Youngnam Cho National Cancer Center Biomarker Branch Contents 1. Liquid Biopsy 2. Circulating Tumor Cells from Blood 3. Cell-free DNA from Blood 1. Liquid biopsy Cancer Diagnosis IMAGING TISSUE BIOPSY
More informationConverting the Hype into Reality: Realizing the Potential of Cell-Free DNA
Converting the Hype into Reality: Realizing the Potential of Cell-Free DNA Lucy Xu, Ph.D. Associate Director Clinical Biomarker Research Eisai Inc. Woodcliff Lake, NJ Precision LBx Summit San Diego, CA
More informationBreast cancer. Prof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA
Breast cancer rof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA Breast cancer Incidence of Breast Cancer by Stage at
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationDr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS
Molecular Profiling of Cancer Cells Strategies for Developing Biomarkers for Targeted Therapies of Cancer Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS Head, Department of Molecular Medicine and
More informationThe detection of differentially expressed micrornas from the serum of ovarian cancer patients using a novel real-time PCR platform
Available online at www.sciencedirect.com Gynecologic Oncology 112 (2009) 55 59 www.elsevier.com/locate/ygyno The detection of differentially expressed micrornas from the serum of ovarian cancer patients
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationOriginal Article High serum mir-203 predicts the poor prognosis in patients with pancreatic cancer
Int J Clin Exp Pathol 2017;10(4):4688-4693 www.ijcep.com /ISSN:1936-2625/IJCEP0047128 Original Article High serum mir-203 predicts the poor prognosis in patients with pancreatic cancer Jun Ma, Xiaokun
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationBCL2 inhibition by ABT-199 in T-cell acute lymphoblastic leukemia (T-ALL)
BCL2 inhibition by ABT-199 in T-cell acute lymphoblastic leukemia (T-ALL) Pieter Van Vlierberghe Bioluminescent Cell-based Assay Seminar Day Monday 31 march 2014 UCL De Duve institute Brussels, Belgium
More information